A Case of Hypercalcemia from PTHrP-Producing Fibromyxoid Sarcoma Responsive to Glucocorticoid Therapy

The treatment of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia of malignancy includes treating the malignancy, intravenous fluids, and anti-resorptive therapies such as zoledronic acid or denosumab. PTHrP-mediated hypercalcemia has been reported in benign conditions such as syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Isabella, Hsiao, Edward C., Wustrack, Rosanna, Wysolmerski, John J., Dann, Pamela, Masharani, Umesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372127/
https://www.ncbi.nlm.nih.gov/pubmed/37358786
http://dx.doi.org/10.1007/s00223-023-01099-8
Descripción
Sumario:The treatment of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia of malignancy includes treating the malignancy, intravenous fluids, and anti-resorptive therapies such as zoledronic acid or denosumab. PTHrP-mediated hypercalcemia has been reported in benign conditions such as systemic lupus erythematous (SLE) and sarcoidosis and appears to be responsive to glucocorticoids. We report a case of PTHrP-induced hypercalcemia due to a malignancy—low grade fibromyxoid sarcoma—that responded to glucocorticoid treatment. This is the first report of glucocorticoids controlling PTHrP-mediated hypercalcemia of malignancy. Immunohistochemistry of the surgical pathology localized PTHrP staining to the vascular endothelial cells within the tumor. Further studies are needed to elucidate the mechanism of glucocorticoid action in the treatment of PTHrP-mediated hypercalcemia of malignancy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00223-023-01099-8.

Ejemplares similares